Integrated Filing- Financial

AstraZeneca Pharma India Ltd has announced a board meeting regarding its financial results for the quarter ended December 31, 2024. The company reported total revenue from operations of ₹4,402.9 million, reflecting a 44% increase year-over-year.

Profit after tax was ₹308.5 million, impacted by exceptional items, including significant restructuring costs related to its Biopharmaceuticals Business Unit.

This strategic move aims to enhance focus on specialist disease areas, including oncology.

Investors may view this strong growth trajectory positively, suggesting potential for future market expansion despite ongoing restructuring challenges.